GleamWall
中文EN

ACAD ACADIA PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1070494 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY14.8%
TTM net income YoY38.7%
TTM EPS YoY36.8%
Revenue 3-yr CAGR23.9%
Net income 3-yr CAGR—

Margins

Gross margin90.5%
Operating margin10.2%
Net margin30.1%
FCF margin6.8%
EBITDA margin10.3%

Returns

ROE31.4%
ROA23.2%
ROIC (approx.)14.2%
Asset turnover0.77x

Leverage & solvency

Liabilities / assets22.7%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.27x
Accruals ratio16.9%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.07B$957.80M
Cost of revenue$89.00M$81.84M
Gross profit$982.51M$875.96M
R&D expense$328.80M$303.25M
SG&A expense$548.89M$488.43M
Operating income$104.81M$230.79M
Pretax income$138.90M$258.07M
Income tax-$252.10M$31.62M
Net income$391.00M$226.45M
EBITDA$105.68M$231.71M
EPS (basic)2.321.37
EPS (diluted)2.301.36
Weighted avg. shares (diluted)169.92M166.36M
Balance sheet
Cash & equivalents$177.69M$319.59M
Short-term investments$641.99M$436.40M
Receivables$121.46M$98.74M
Inventory$111.37M$91.69M
Current assets$1.06B$938.32M
PP&E, net$7.51M$4.21M
Intangibles$108.89M$119.78M
Total assets$1.56B$1.19B
Current liabilities$277.11M$394.87M
Total liabilities$336.81M$454.96M
Shareholders' equity$1.23B$732.79M
Shares outstanding170.31M166.71M
Cash flow statement
Operating cash flow$109.84M$157.72M
Capital expenditure$4.69M$523,000
Free cash flow$105.15M$157.20M
Investing cash flow-$302.56M-$30.54M
Financing cash flow$49.88M$6.84M
Depreciation & amortization$871,000$920,000
Stock-based compensation$52.13M$67.05M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.